By Nana O 
High-grade glioma, a formidable and aggressive brain cancer affecting both children and adults, presents a formidable therapeutic challenge. Its insidious nature stems from a confluence of factors: the critical and often inaccessible tumor locations within the brain, a high propensity for recurrence, and the formidable barrier posed by the blood-brain barrier, which severely limits the efficacy of many conventional drug therapies. In a significant stride toward overcoming these hurdles, a collaborative effort involving researchers from the University of Michigan, Dana Farber Cancer Institute, and the Medical University of Vienna has illuminated a potential new avenue for treating this devastating disease. Their groundbreaking study, published in the esteemed journal Cancer Cell, reveals that avapritinib, a drug already recognized by the U.S. Food and Drug Administration for its efficacy in treating specific forms of gastrointestinal stromal tumors and systemic mastocytosis, demonstrates a compelling response in high-grade glioma tumor cells that harbor DNA alterations in the PDGFRA gene.
Unveiling the PDGFRA Pathway as a Therapeutic Target
The PDGFRA gene, identified as one of the most frequently mutated genes in high-grade gliomas, has long been a focal point for researchers seeking to disrupt the aggressive growth mechanisms of these tumors. "Aside from surgery and radiation, there aren’t effective drugs to treat high-grade gliomas, especially upon recurrence," explained Dr. Carl Koschmann, the study’s senior author and a leading figure in pediatric brain tumor research at the University of Michigan. "We were excited to see that avapritinib essentially shut off PDGFRA signaling in mouse brain tumors," he added, underscoring the direct impact of the drug on a key driver of tumor progression.
The research team, comprising experts from across multiple leading institutions, embarked on a systematic investigation into the potential of PDGFRA inhibitors. Through extensive screening of commercially available drugs, avapritinib emerged as a standout candidate. "We’d been doing screens with a lot of commercially available drugs that inhibit PDGFRA," Dr. Koschmann stated. "We found avapritinib to be the strongest and most focused inhibitor that targets PDGFRA alterations." This focused inhibition is crucial in the complex landscape of cancer therapy, aiming to maximize therapeutic effect while minimizing off-target side effects.
Crossing the Blood-Brain Barrier: A Critical Hurdle Overcome
A significant challenge in treating brain cancers is the blood-brain barrier (BBB), a highly selective physiological barrier that protects the central nervous system from circulating toxins but also impedes the passage of therapeutic agents. The ability of a drug to effectively penetrate this barrier is paramount to its success in treating brain tumors. The collaborative team, including colleagues from the laboratories of Dr. Mariella Filbin at Dana Farber Cancer Institute and Dr. Johannes Gojo at the Medical University of Vienna, who were concurrently investigating the efficacy of PDGFRA inhibitors, were particularly encouraged by avapritinib’s ability to traverse this protective shield.
"When we gave mice the drug and showed that it reached the brain, we knew we were onto something," expressed Kallen Schwark, an M.D./Ph.D. student at the University of Michigan and one of the study’s lead authors. This critical finding validated the preclinical rationale for avapritinib’s potential as a brain-penetrant therapy for high-grade gliomas. The ability of avapritinib to effectively reach the tumor site within the brain is a game-changer, opening up possibilities for treatment that were previously limited.
Clinical Translation: Early Human Trials and Promising Outcomes
Building on the robust preclinical data, the researchers moved swiftly to explore avapritinib’s therapeutic potential in human patients. Through an expanded access program facilitated by the drug’s manufacturer, Blueprint Medicines, and while a formal clinical trial was still in its nascent stages, the team was able to treat the first cohort of patients diagnosed with high-grade glioma. "Across multiple international institutions, we treated the first eight patients with high-grade glioma with avapritinib," Dr. Koschmann reported.
The results from this early clinical experience were encouraging. "The patients tolerated the drug well and in three of the eight patients, we were able to see their tumors shrink," he continued. This observed tumor reduction in a subset of patients, despite the aggressive nature of the disease and limited prior treatment options, provides a critical foundation for further investigation. The positive early outcomes in humans, coupled with the compelling preclinical data, were instrumental in informing the design of subsequent clinical trials.
The Path Forward: Clinical Trials and Future Combinatorial Therapies
The promising early data has directly paved the way for further clinical evaluation. The inclusion of pediatric high-grade glioma in a Phase I pediatric solid tumor trial, which has recently completed patient accrual and is currently undergoing analysis, represents a significant milestone. This trial aims to rigorously assess the safety and efficacy of avapritinib in a broader pediatric patient population.
"We have very few examples of drugs entering brain tumors like this and shutting down key oncogenic pathways," Dr. Koschmann emphasized. "These results support a lot of ongoing efforts to build on the success of avapritinib and other brain penetrant small molecule inhibitors." The success of avapritinib in targeting a specific genetic alteration within high-grade glioma offers a paradigm shift, moving away from broad-spectrum treatments towards more precision-based therapies.
High-grade gliomas are notoriously aggressive, with a grim prognosis often measured at less than two years and historically limited effective treatment options beyond surgery and radiation. While the current findings are preliminary, Dr. Koschmann expressed cautious optimism regarding avapritinib’s potential to become a valuable addition to the therapeutic arsenal. "We know a single drug is not going to be enough for this disease," he acknowledged. "The way to make true progress will be combining many different types of modalities, like combining drugs that are target pathways activated by the first drug."
This forward-thinking approach is already underway, with the team actively pursuing the next steps in research. "We already have a follow-up story on targeting avapritinib with MAP kinase inhibitors that we are just as excited about," Dr. Koschmann revealed, highlighting the potential for synergistic therapeutic strategies. The development of combinatorial therapies, where drugs targeting different but interconnected pathways are used in tandem, is widely recognized as a crucial strategy for overcoming drug resistance and achieving more durable responses in complex cancers like high-grade glioma.
Broader Implications and the Evolving Landscape of Brain Cancer Treatment
The success of avapritinib in targeting PDGFRA alterations in high-grade glioma has significant implications for the broader field of neuro-oncology. It underscores the power of genomic profiling in identifying actionable mutations and developing targeted therapies. As our understanding of the molecular drivers of brain tumors continues to deepen, the ability to identify specific genetic vulnerabilities, such as PDGFRA mutations, will become increasingly critical.
This research also highlights the importance of international collaboration in tackling rare and aggressive diseases. By pooling resources, expertise, and patient populations, researchers can accelerate the pace of discovery and translation of promising findings from the laboratory to the clinic. The journey from initial discovery to clinical application is often long and arduous, but this collaborative model appears to be a highly effective approach for advancing the treatment of complex cancers.
Furthermore, the development of drugs that can effectively penetrate the blood-brain barrier remains a paramount goal in neuro-oncology. Avapritinib’s demonstrated brain penetrance represents a significant advancement in this area, potentially opening doors for other targeted therapies that have previously been hindered by this obstacle. The ongoing research into brain-penetrant small molecule inhibitors, inspired by findings like these, promises to expand the therapeutic landscape for a range of neurological conditions, not just cancers.
While the path to a definitive cure for high-grade glioma is still being forged, the progress achieved with avapritinib offers a beacon of hope. The ability to precisely target a key genetic driver of the cancer, coupled with the drug’s capacity to reach the tumor site, represents a substantial leap forward. The ongoing clinical trials and the exploration of combinatorial therapies suggest a future where high-grade glioma may be managed with greater efficacy and improved outcomes for patients, offering a renewed sense of possibility in the fight against this devastating disease. The scientific community will be closely watching the results of ongoing analyses and future clinical studies, eager to see how this promising development will ultimately shape the treatment paradigm for high-grade glioma.
